Cover Image
Market Research Report

Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021

Published by MarketsandMarkets Product code 335087
Published Content info 262 Pages
Delivery time: 1-2 business days
Price
Back to Top
Tumor Ablation Market by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021
Published: October 5, 2016 Content info: 262 Pages
Description

"Tumor Ablation Market - by Technology (Radiofrequency, Microwave, Cryoablation, IRE, Ultrasound, Laser), Mode of Treatment (Surgical, Laparoscopic, Percutaneous), Application (Liver, Lung, Kidney, Bone Metastasis, Prostate, Breast) - Global Forecast 2021"

The global tumor ablation market is estimated to register a high CAGR of 12.5% during 2016-2021, and is expected to be valued at ~USD 580.1 million in 2021. Although mature markets (North America and Europe) held large shares of the tumor ablation market in 2016, the Asia-Pacific region is projected to register the highest growth during the next five years. A number of factors such as technological advancements in the field of tumor ablation focused on enhancing effectiveness and safety of the treatment, rising demand of minimal invasive tumor ablation techniques, increasing prevalence of cancer across the globe, and growing public-private initiatives and funding to support R&D activities in tumor ablation are propelling the growth of the market. However, factors such as unfavorable regulatory policies and cost-containment measures adopted by various governments are restraining the optimal market growth.

On the basis of technology, the global tumor ablation market is divided into four major categories, namely, radiofrequency ablation, microwave ablation, cryoablation, and others (includes electrical, laser/light, ultrasound). Based on mode of treatment, the tumor ablation market is segmented into surgical mode, laparoscopic mode, and percutaneous mode. On the basis of application of tumor ablation, the market is categorized into liver cancer, lung cancer, kidney/renal cancer, bone metastasis, and others (includes tumor ablation for the treatment of prostate, breast, colorectal, thyroid, pancreas, neuroendocrine, head, neck, and lumbar-vertebra cancer).

Geographically, North America is estimated to command the largest share of the global tumor ablation market in 2016, followed by Europe. The high prevalence and incidence of major types of cancer (such as liver, lung, kidney, and bone metastasis) in the region, rising inclination of patients towards minimally invasive procedures for cancer treatment, and increasing government funding for cancer research are market drivers in North America. However, unsupportive government policies, limited availability of medical reimbursements in the U.S., and cost-containment measures adopted by governments in the U.S. and Canada are negatively affecting the growth of the tumor ablation market in this region.

The tumor ablation market is fairly competitive, with a large number of global and local manufacturers of tumor ablation solutions. Medtronic plc (Ireland), AngioDynamics, Inc. (U.S.), and HealthTronics, Inc. (U.S.) were the top three players in the tumor ablation market in 2015. New product launches and product enhancements; acquisitions; geographic expansions; and partnerships, agreements, and collaborations are the major strategies adopted by most players to achieve growth in the tumor ablation market.

Benefits of Buying the Report:

This report studies tumor ablation market based on technologies, modes of treatment, and applications. The report also studies, factors (such as drivers, restraints, opportunities, and challenges) which positively and negatively affect market growth. It analyzes opportunities and challenges in the market for stakeholders, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes the micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market.

Table of Contents
Product Code: MD 3271

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. GEOGRAPHIC SCOPE
    • 1.3.3. YEARS CONSIDERED FOR THE STUDY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH DATA
    • 2.1.1. SECONDARY DATA
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY DATA
      • 2.1.2.1. Key data from primary sources
  • 2.2. OPPORTUNITY INDICATORS
    • 2.2.1. DEMAND-SIDE ANALYSIS
    • 2.2.2. SUPPLY-SIDE ANALYSIS
  • 2.3. MARKET SIZE ESTIMATION
  • 2.4. MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5. RESEARCH ASSUMPTIONS

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CURRENT MARKET SCENARIO
  • 3.3. FUTURE OUTLOOK
  • 3.4. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. MARKET OPPORTUNITIES FOR GROWTH IN TUMOR ABLATION MARKET (2016-2021)
  • 4.2. NORTH AMERICA TO COMMAND THE LARGEST SHARE OF TUMOR ABLATION MARKET FOR ALL MODES OF TREATMENT (2016)
  • 4.3. CHINA AND INDIA TO LEAD THE MARKET GROWTH FOR TUMOR ABLATION TECHNOLOGIES DURING THE FORECAST PERIOD
  • 4.4. CHINA AND INDIA TO LEAD THE MARKET DEMAND FOR MICROWAVE AND CRYOABLATION-BASED TUMOR ABLATION PRODUCTS (2016-2021)
  • 4.5. LIVER CANCER HOLDS THE LARGEST SHARE IN TUMOR ABLATION MARKET IN 2016
  • 4.6. MEDTRONIC, PLC DOMINATED THE TUMOR ABLATION MARKET IN 2015

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET EVOLUTION
  • 5.3. MARKET DYNAMICS
    • 5.3.1. IMPACT ANALYSIS
    • 5.3.2. KEY MARKET DRIVERS
      • 5.3.2.1. Rising prevalence of cancer
      • 5.3.2.2. Technological advancements in the field of thermal ablation
      • 5.3.3.3. Rising market demand for minimally invasive surgeries
      • 5.3.3.4. Increasing public-private funding for product development and Commercialization
      • 5.3.3.5. Growing number of hospitals and surgical & ablation centers
    • 5.3.3. KEY MARKET RESTRAINTS
      • 5.3.3.1. Unfavorable regulatory scenario
      • 5.3.3.2. Cost-containment measures adopted by various regional governments
    • 5.3.4. KEY MARKET OPPORTUNITIES
      • 5.3.4.1. Improving healthcare infrastructure across emerging countries
      • 5.3.4.2. Increasing patient awareness about the therapeutic benefits of tumor ablation
      • 5.3.4.3. Evolving reimbursement scenario
    • 5.3.5. KEY MARKET CHALLENGES
      • 5.3.5.1. Therapeutic challenges related to tumor ablation procedures

6. INDUSTRY INSIGHTS

  • 6.1. INTRODUCTION
  • 6.2. VALUE CHAIN ANALYSIS
  • 6.3. INDUSTRY TRENDS
    • 6.3.1. GROWING ADOPTION RATE OF RADIOFREQUENCY-BASED TUMOR ABLATION PROCEDURES
    • 6.3.2. GROWING MARKET FOCUS ON THE DEVELOPMENT OF NOVEL MICROWAVE-BASED TUMOR ABLATION PRODUCTS
  • 6.4. PORTER'S FIVE FORCE ANALYSIS
    • 6.4.1. OVERVIEW
    • 6.4.2. THREAT FROM NEW ENTRANTS
    • 6.4.3. THREAT OF SUBSTITUTES
    • 6.4.4. BARGAINING POWER OF SUPPLIERS
    • 6.4.5. BARGAINING POWER OF BUYERS
    • 6.4.6. INTENSITY OF COMPETITIVE RIVALRY

7. TUMOR ABLATION TECHNOLOGY MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. RADIOFREQUENCY (RF) ABLATION
  • 7.3. MICROWAVE ABLATION
  • 7.4. CRYOABLATION
  • 7.5. OTHER TECHNOLOGIES

8. TUMOR ABLATION TECHNOLOGY MARKET, BY MODE OF TREATMENT

  • 8.1. INTRODUCTION
  • 8.2. SURGICAL ABLATION
  • 8.3. LAPAROSCOPIC ABLATION
  • 8.4. PERCUTANEOUS ABLATION

9. TUMOR ABLATION TECHNOLOGY MARKET, BY APPLICATION

  • 9.1. INTRODUCTION
  • 9.2. LIVER CANCER ABLATION
  • 9.3. LUNG CANCER ABLATION
  • 9.4. KIDNEY CANCER ABLATION
  • 9.5. BONE METASTASIS ABLATION
  • 9.6. OTHER APPLICATIONS

10. TUMOR ABLATION TECHNOLOGY MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. U.S.
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. ITALY
    • 10.3.2. GERMANY
    • 10.3.3. FRANCE
    • 10.3.4. U.K.
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE (ROE)
  • 10.4. ASIA-PACIFIC
    • 10.4.1. JAPAN
    • 10.4.2. CHINA
    • 10.4.3. INDIA
    • 10.4.4. REST OF ASIA-PACIFIC (ROAPAC)
  • 10.5. REST OF THE WORLD (ROW)

11. COMPETITIVE LANDSCAPE

  • 11.1. INTRODUCTION
  • 11.2. MARKET SHARE ANALYSIS, BY KEY PLAYER (2015)
  • 11.3. COMPETITIVE SCENARIO
  • 11.4. RECENT DEVELOPMENTS
    • 11.4.1. PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS
    • 11.4.2. DIVESTMENTS AND ACQUISITIONS
    • 11.4.3. GEOGRAPHIC EXPANSION
    • 11.4.4. AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 11.4.5. OTHER DEVELOPMENTS

12. COMPANY PROFILES

  • 12.1. INTRODUCTION
    • 12.1.1. GEOGRAPHIC BENCHMARKING
    • 12.1.2. KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
  • 12.2. ANGIODYNAMICS, INC. (U.S.)
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. MNM VIEW
    • 12.2.3. ANGIODYNAMICS, INC. - COMPANY SNAPSHOT
    • 12.2.4. PRODUCT PORTFOLIO
    • 12.2.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.3. BOSTON SCIENTIFIC CORPORATION (U.S)
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. MNM VIEW
    • 12.3.3. BOSTON SCIENTIFIC CORPORATION - COMPANY SNAPSHOT
    • 12.3.4. PRODUCT PORTFOLIO
    • 12.3.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.4. GALIL MEDICAL, INC. (U.S.)
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. MNM VIEW
    • 12.4.3. BTG INTERNATIONAL LTD.- COMPANY SNAPSHOT
    • 12.4.4. PRODUCT PORTFOLIO
    • 12.4.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.5. EDAP TMS S.A. (FRANCE)
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. EDAP TMS S.A. - COMPANY SNAPSHOT*
    • 12.5.3. PRODUCT PORTFOLIO
    • 12.5.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.6. HEALTHTRONICS, INC. (U.S.) [A BUSINESS SEGMENT OF ALTARIS CAPITAL PARTNERS, LLC (U.S.)]
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. MNM VIEW
    • 12.6.3. PRODUCT PORTFOLIO
    • 12.6.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.7. MEDTRONIC PLC (IRELAND)
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. MNM VIEW
    • 12.7.3. MEDTRONIC PLC - COMPANY SNAPSHOT
    • 12.7.4. PRODUCT PORTFOLIO
    • 12.7.5. RECENT DEVELOPMENTS (2013-2016)
  • 12.8. MERMAID MEDICAL, INC. (DENMARK)
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. PRODUCT PORTFOLIO
    • 12.8.3. RECENT DEVELOPMENTS (2013-2016)
  • 12.9. MISONIX, INC. (U.S)
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. MISONIX, INC. - COMPANY SNAPSHOT
    • 12.9.3. PRODUCT PORTFOLIO
    • 12.9.4. RECENT DEVELOPMENTS (2013-2016)
  • 12.10. NEUWAVE MEDICAL, INC. (U.S) (ACQUIRED BY ETHICON - J&J GROUP OF COMPANY)
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. PRODUCT PORTFOLIO
    • 12.10.3. RECENT DEVELOPMENTS (2013-2016)
  • 12.11. SONACARE MEDICAL, LLC (U.S)
    • 12.11.1. COMPANY OVERVIEW
    • 12.11.2. PRODUCT PORTFOLIO
    • 12.11.4. RECENT DEVELOPMENTS (2013-2016)

13. APPENDIX

  • 13.1. INSIGHTS FROM INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS

LIST OF TABLES

  • TABLE 1: GLOBAL TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 2: TUMOR ABLATION MARKET SIZE FOR RF ABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 3: TUMOR ABLATION MARKET SIZE FOR MICROWAVE ABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 4: TUMOR ABLATION MARKET SIZE FOR CRYOABLATION TECHNOLOGY, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: TUMOR ABLATION MARKET SIZE FOR OTHER TECHNOLOGIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 6: GLOBAL TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 7: CLINICAL PERSPECTIVE OF KEY HEPATOCELLULAR CARCINOMA SURGICAL TREATMENT MODES - A COMPARATIVE STUDY
  • TABLE 8: TUMOR ABLATION MARKET SIZE FOR SURGICAL MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 9: TUMOR ABLATION MARKET SIZE FOR LAPAROSCOPIC MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 10: TUMOR ABLATION MARKET SIZE FOR PERCUTANEOUS MODE OF TREATMENT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: KEY PERCUTANEOUS TUMOR ABLATION TECHNOLOGIES - A COMPARATIVE STUDY
  • TABLE 12: GLOBAL TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 13: TUMOR ABLATION MARKET SIZE FOR LIVER CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: LIVER CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 15: TUMOR ABLATION MARKET SIZE FOR LUNG CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 16: LUNG CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 17: TUMOR ABLATION MARKET SIZE FOR KIDNEY CANCER APPLICATION, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 18: KIDNEY CANCER ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 19: TUMOR ABLATION MARKET SIZE FOR BONE METASTASIS APPLICATION, Y REGION, 2014-2021 (USD MILLION)
  • TABLE 20: BONE METASTASIS ABLATION MARKET-INFLUENCING FACTORS
  • TABLE 21: TUMOR ABLATION MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 22: GLOBAL TUMOR ABLATION MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 23: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 24: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 25: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 26: NORTH AMERICA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 27: U.S.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 28: U.S.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 29: U.S.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 30: CANADA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 31: CANADA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 32: CANADA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 33: EUROPE: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 34: EUROPE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 35: EUROPE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 36: EUROPE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 37: ITALY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 38: ITALY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 39: ITALY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 40: GERMANY: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 41: GERMANY: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 42: GERMANY: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 43: FRANCE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014- 2021 (USD MILLION)
  • TABLE 44: FRANCE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 45: FRANCE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 46: U.K.: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 47: U.K.: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 48: U.K.: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 49: SPAIN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 50: SPAIN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 51: SPAIN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 52: ROE: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 53: ROE: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 54: ROE: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 55: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY COUNTRY/REGION, 2014-2021 (USD MILLION)
  • TABLE 56: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 57: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 58: ASIA-PACIFIC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 59: JAPAN: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 60: JAPAN: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 61: JAPAN: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 62: CHINA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 63: CHINA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 64: CHINA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 65: INDIA: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 66: INDIA: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 67: INDIA: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 68: ROAPAC: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 69: ROAPAC: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 70: ROAPAC: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 71: ROW: TUMOR ABLATION MARKET SIZE, BY TECHNOLOGY, 2014-2021 (USD MILLION)
  • TABLE 72: ROW: TUMOR ABLATION MARKET SIZE, BY MODE OF TREATMENT, 2014-2021 (USD MILLION)
  • TABLE 73: ROW: TUMOR ABLATION MARKET SIZE, BY APPLICATION, 2014-2021 (USD MILLION)
  • TABLE 74: PIPELINE DEVELOPMENTS AND PRODUCT ENHANCEMENTS (2013-2016)
  • TABLE 75: DIVESTMENTS AND ACQUISITIONS (2013-2016)
  • TABLE 76: GEOGRAPHIC EXPANSIONS (2013-2016)
  • TABLE 77: AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS (2013-2016)
  • TABLE 78: OTHER DEVELOPMENTS (2013-2016)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: NUMBER OF NEW CANCER CASES, BY COUNTRY: 2012 VS. 2020
  • FIGURE 3: INCREASING INCIDENCES OF CANCERS, BY SITE: 2012-2020
  • FIGURE 4: INCREASE IN AGING POPULATION, BY COUNTRY: 2010 VS. 2015
  • FIGURE 5: PERCENTAGE INCREASE IN AGING POPULATION, BY REGION: (1980-2010) VS. (2010-2040)
  • FIGURE 6: HEALTHCARE EXPENDITURE ACROSS MAJOR COUNTRIES: 2000-2014
  • FIGURE 7: HEALTHCARE EXPENDITURE ACROSS MAJOR REGIONS: 2000-2014
  • FIGURE 8: SIGNIFICANT AVAILABILITY OF PUBLIC-PRIVATE INVESTMENTS TO SUPPORT TUMOR ABLATION-BASED RESEARCHES: LED BY U.S., CHINA AND EUROPE
  • FIGURE 9: TUMOR ABLATION IS EXPECTED TO BE THE FASTEST-GROWING ABLATION TECHNOLOGY APPLICATION SEGMENT TILL 2021
  • FIGURE 10: NUMBER OF NEW PRODUCT LAUNCHES: TUMOR ABLATION MARKET (2013-2016)
  • FIGURE 11: MARKET SIZE ESTIMATION
  • FIGURE 12: TUMOR ABLATION MARKET, BY COUNTRY/REGION (2016-2021)
  • FIGURE 13: TUMOR ABLATION MARKET: REGIONAL SCENARIO (2016)
  • FIGURE 14: GLOBAL TUMOR ABLATION MARKET FUTURE TRENDS, BY MODE OF TREATMENT AND APPLICATION (2016-2021)
  • FIGURE 15: GLOBAL PREVALENCE OF CANCER: EXPECTED TREND FOR 2012 VS. 2015 VS. 2020
  • FIGURE 16: KEY TUMOR ABLATION MARKETS: CHANGING PROPORTION OF GERIATRIC INDIVIDUALS IN THE TOTAL POPULATION (2012 VS. 2020)
  • FIGURE 17: PERCENTAGE CHANGE IN HEALTHCARE EXPENDITURE: DEVELOPED VS. DEVELOPING NATIONS (2005-2014)
  • FIGURE 18: TUMOR ABLATION MARKET, BY TECHNOLOGY: GROWTH FORECAST DURING 2016-2021
  • FIGURE 19: TUMOR ABLATION MARKET SHARE FOR RF TECHNOLOGY, BY REGION (2016)
  • FIGURE 20: TUMOR ABLATION MARKET SHARE FOR MICROWAVE TECHNOLOGY, BY REGION (2016)
  • FIGURE 21: TUMOR ABLATION MARKET SHARE FOR CRYOABLATION TECHNOLOGY, BY REGION (2016)
  • FIGURE 22: TUMOR ABLATION MARKET SHARE FOR OTHER TECHNOLOGIES, BY REGION (2016)
  • FIGURE 23: TUMOR ABLATION MARKET, BY MODE OF TREATMENT: GROWTH FORECAST DURING 2016-2021
  • FIGURE 24: TUMOR ABLATION MARKET FOR SURGICAL MODE OF TREATMENT, BY REGION (2016)
  • FIGURE 25: TUMOR ABLATION MARKET FOR LAPAROSCOPIC MODE, BY REGION (2016)
  • FIGURE 26: TUMOR ABLATION MARKET FOR PERCUTANEOUS MODE, BY REGION (2016)
  • FIGURE 27: TUMOR ABLATION MARKET, BY APPLICATION: GROWTH FORECAST DURING 2016-2021
  • FIGURE 28: TUMOR ABLATION MARKET SHARE FOR LIVER CANCER, BY REGION (2016)
  • FIGURE 29: TUMOR ABLATION MARKET SHARE FOR LUNG CANCER, BY REGION (2016)
  • FIGURE 30: TUMOR ABLATION MARKET SHARE FOR KIDNEY CANCER, BY REGION (2016)
  • FIGURE 31: TUMOR ABLATION MARKET SHARE FOR BONE METASTASIS, BY REGION (2016)
  • FIGURE 32: TUMOR ABLATION MARKET SHARE FOR OTHER APPLICATIONS, BY REGION (2016)
  • FIGURE 33: NORTH AMERICAN TUMOR ABLATION MARKET: EXPECTED TRENDS (2016 VS. 2021)
  • FIGURE 34: NORTH AMERICA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 35: U.S.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 36: U.S.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 37: U.S.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 38: CANADA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 39: CANADA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 40: CANADA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 41: EUROPEAN TUMOR ABLATION MARKET: EXPECTED TRENDS (2016 VS. 2021)
  • FIGURE 42: EU5: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 43: ITALY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 44: ITALY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 45: ITALY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 46: GERMANY: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 47: GERMANY: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 48: GERMANY: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 49: FRANCE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 50: FRANCE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 51: FRANCE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 52: U.K.: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 53: U.K.: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 54: U.K.: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 55: SPAIN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 56: SPAIN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 57: SPAIN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 58: ROE: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 59: ROE: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 60: ROE: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 61: ASIA-PACIFIC TUMOR ABLATION MARKET: EXPECTED TREND (2016 VS. 2021)
  • FIGURE 62: ASIA-PACIFIC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 63: JAPAN: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 64: JAPAN: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 65: JAPAN: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 66: CHINA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 67: CHINA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 68: CHINA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 69: INDIA: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 70: INDIA: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 71: INDIA: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 72: ROAPAC: TUMOR ABLATION MARKET SHARE, BY TECHNOLOGY (2016)
  • FIGURE 73: ROAPAC: TUMOR ABLATION MARKET SHARE, BY MODE OF TREATMENT (2016)
  • FIGURE 74: ROAPAC: TUMOR ABLATION MARKET SHARE, BY APPLICATION (2016)
  • FIGURE 75: ROW TUMOR ABLATION MARKET: EXPECTED TREND (2016 VS. 2021)
  • FIGURE 76: LEADING MARKET PLAYERS ADOPTED PRODUCT DEVELOPMENT AND COMMERCIALIZATION AS KEY GROWTH STRATEGIES DURING 2013-2016
  • FIGURE 77: TUMOR ABLATION MARKET SHARE, BY KEY PLAYER (2015)
  • FIGURE 78: KEY GROWTH STRATEGIES, BY YEAR (2013-2016)
  • FIGURE 79: PRODUCT DEVELOPMENT, THE MOST WIDELY ADOPTED GROWTH STRATEGY DURING 2013-2016
  • FIGURE 80: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS: TUMOR ABLATION MARKET (2015)
  • FIGURE 81: PIPELINE DEVELOPMENT AND PRODUCT ENHANCEMENT IS THE KEY STRATEGY PURSUED BY TOP PLAYERS TO INCREASE THEIR TUMOR ABLATION MARKET REVENUE
Back to Top